The life science industry is discovering new paths to extract business value as they adopt the cloud. In his opening remarks, Vineet Jain recaps the past year and what is on the horizon for Egnyte as it continues to deliver value to the life science industry.
Join Dr. Nimita Limaye, Research VP, Life Sciences R&D Strategy and Technology at IDC, as she reviews the top technology trends for 2022, including patient centricity, digital transformation, and AI.
Over 700 Life Science organizations are able to extract value from Egnyte's platform for Life Science. In continuing our commitment to the LS industry, Ronen Vengosh shares Egnyte's product direction, including products released over the past year and our latest module for biotechs, eTMF.
Learn how life sciences venture capital firm, Third Rock Ventures, implements a tech stack founded on Egnyte that provides support for the data needs of the modern high-growth, data-intensive biotechs throughout their growth journey.
Gathering insight from the massive amount of data produced during the R&D lifecycle of any therapeutic agent research is challenging. The pandemic has highlighted the need to improve our capability to plan, execute and analyze research in a remote environment. Nate McBride, VP of IT at Affinivax, will discuss how the “lab-in-the-cloud” approach can help accelerate research in a collaborative and secure environment.
Developing new medicines is risky and costly. Recent public market volatility has led the $XBI (ETF that tracks the performance of the S&P® Biotechnology Index) to fall 60% from its 2021 high to the 2022 trough. In this light, biotech companies need to be creative in obtaining financing to support the development of needed medicines. In this session, Alok Tayi, founder of VIBE Bio DAO, will discuss innovative ways of capitalizing on programs & companies such that the organization has the resources required to help patients with novel medicines.
Decentralized Clinical Trials (DCTs) have increased in popularity during the pandemic. DCTs tout better patient participation, lower dropout rates, and more diverse patient pools. But as the world opens up and traditional clinical trial capacity returns to pre-pandemic levels, will DCTs maintain their popularity? Join industry experts from Bristol Myers Squibb (BMS) and Thread(R) as they discuss the merits and future of DCTs.
The estimated value of blockchain technology to the life sciences sector is predicted to be somewhere between $3B and $5.6B by 2025, primarily due to the imperative for secure communication between stakeholders organizing clinical trials. Join the discussion to learn how life science companies are starting to leverage blockchain technology to improve data integrity, security, and accessibility in modern clinical trials.
Phillip Doyle from Doyle GxP discusses GxP principles for small biotechs. Covering areas such as when in the drug development journey quality and compliance principles should apply, how to apply them, and why GxP guidelines are important for creating an early culture of quality, you won't want to miss this session.
As complexity increases, trial managers are looking to technology to help reduce the administrative burden. Join Marion Mays as she looks at the past, present and future of eTMF development.
The traditionally risk-averse clinical trial industry has started to explore more advanced technologies in order to evolve how trials are run - exploring topics like real-world data capture, decentralized trial execution, faster patient enrollment, and better trial data analytics. In this session, learn how these new technologies are enabling smarter trial design, intended to generate better insights and accelerate time to patient.
Scientists can now generate more data in a single day than they could in the preceding decade. Today, translating this deluge of data into actionable insights has become the rate-limiting step to scientific discovery. Researchers struggle to access the computational infrastructure, niche informatics tooling, and data science expertise required to realize the full potential of their experiments. Dr. Mark Kalinich discusses these challenges, reviews the available solutions, and shares how a fully-integrated Bio-IT platform can accelerate scientific discovery and the development of targeted therapeutics and diagnostics.
Access to quality data is one of the most important accelerators of growth for emerging biotechs. The resulting analysis and insights are enabling a golden age for research and therapy development as modern drug development teams are leveraging technology to unlock scientific data in new ways. Join this discussion to learn about digital workflow automation and the development of NIMBEye, Nimbus’ cloud computing environment that has accelerated the deployment of CRO data from days to minutes.
The use of AI in drug discovery has yielded interesting candidates and new ways of "in silico" testing. Join industry expert Brandon Allgood, Chief AI Officer at Valo Health, in a discussion of how innovative biotechs are using AI as a competitive advantage in drug discovery and clinical trials.
The ability to take a promising idea to build phase is a long and winding path. Building an operational framework that is scalable and flexible enough for modern biotechs is what allows for hypergrowth. Join this panel of top-tier VCs as they provide insight, trends, and lessons learned for launching successful early-stage companies.
The data challenges facing nimble biotechs can’t just be solved with more headcount and employing the latest technology. Cutting-edge strategies and tried and true tactics are needed to create modern data infrastructures that can glean insight out of chaos. Join Scott Sacane, Founder and CEO of Catalytic Data Science as he reviews the challenges of modern data management and how we can build processes that are scalable, secure, and compliant.
With sensitive company data and even more sensitive patient data, life sciences firms are at constant risk of a data breach. Whether the incident is caused by a malicious actor or results from a simple mistake, protecting data needs to be top of mind for every company. Join Robert Kuhn, Director of IT Infrastructure & Security at Travere Therapeutics, and Neil Jones, Cybersecurity Evangelist at Egnyte, as they examine the most pressing cybersecurity threats and outline practical steps to protect your organization.
Successful emerging life sciences companies have an early understanding of compliance guidelines, including when to implement GLP, GMP, and GCP workflows, technologies and best practices. Marching too fast can be costly and slow down development; going too slow can result in additional regulatory scrutiny and delays. David Grote, Head of Quality at Immunocore outlines how to identify when to apply compliance principles in the drug development journey, and how to implement GxP guidances, workflows, helpful technologies, and best practices.
Ask the Experts. Join an informal live chat hosted by Egnyte's Product Team as they answer any questions you have on the new eTMF solution, existing features and functionality, and future roadmap.
Effective administration is an essential aspect of every data management platform. Join Logan Smith as he takes questions, walks through everyday use cases, and gives practical tips in administering the core capabilities of the Egnyte for Life Sciences platform.